APA (7th ed.) Citation

YS, W., EA, B., F, H., M, B., F, O., C, B., . . . E, A. (2026). Integrating Structured Expert Elicitation with External Evidence to Inform Earlier Reimbursement Decisions: A Norwegian Case Study of Selpercatinib for Non-Small Cell Lung Cancer. PharmacoEconomics - open, 10(4), 679. https://doi.org/10.1007/s41669-026-00656-9

Chicago Style (17th ed.) Citation

YS, Wu, Burger EA, Holmboe F, Bangum M, Oteiza F, Bugge C, Sæther EM, and Aas E. "Integrating Structured Expert Elicitation with External Evidence to Inform Earlier Reimbursement Decisions: A Norwegian Case Study of Selpercatinib for Non-Small Cell Lung Cancer." PharmacoEconomics - Open 10, no. 4 (2026): 679. https://doi.org/10.1007/s41669-026-00656-9.

MLA (9th ed.) Citation

YS, Wu, et al. "Integrating Structured Expert Elicitation with External Evidence to Inform Earlier Reimbursement Decisions: A Norwegian Case Study of Selpercatinib for Non-Small Cell Lung Cancer." PharmacoEconomics - Open, vol. 10, no. 4, 2026, p. 679, https://doi.org/10.1007/s41669-026-00656-9.